Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

Revenues for JUBLPHARMA are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 0.00000
forwardPE 24.03719
debtToEquity 43.86700
earningsGrowth -0.44700
revenueGrowth 0.16500
grossMargins 0.64945
operatingMargins 0.07953
trailingEps 27.22000
forwardEps 36.30000

Jubilant Pharmova Limited's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Jubilant Pharmova Limited's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
Jubilant Pharmova Limited's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
JUBLPHARMA's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that JUBLPHARMA is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

The present price of JUBLPHARMA in relation to its projections indicates a lack of clear risks or opportunities. This balanced situation suggests that investors may find it prudent to wait for further signals before making significant moves in the stock.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


Jubilant Pharmova Limited had 4 buy transactions while market price was at 1068.9750061035156 per share.Throughout the period under consideration, there were no buy transactions.Jubilant Pharmova Limited's current price levels are experiencing more selling activity, which could signal bearish sentiment. If this trend continues, it may lead to further price declines, as increased selling pressure typically indicates investor concerns about the stock's future performance.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


Analysts are favoring Jubilant Pharmova Limited with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider Jubilant Pharmova Limited as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.